Previous observational multi‐country studies have recently shown that parts of the EMPA‐REG OUTCOME and CANVAS trial results do translate to the SGLT‐2 inhibitor class, and into a real‐world setting with patients with T2D having broader CV risk profiles3, 4, 6, 7, 30; however, by using a wider range of outcomes, the present paper further adds to this knowledge base by showing that a specific SGLT‐2 inhibitor, dapagliflozin, is associated with lower CV risk in a real‐world setting compared with a widely used GLD class, DPP‐4 inhibitors. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.